Hemofarm acquires BIOTA intima brand

The BIOTA intima brand has become a new member of the Hemofarm portfolio. This acquisition represents another step in enriching Hemofarm's offer for women's health, all in line with the company's purpose to be a reliable partner in caring for people's health.

Hemofarm’s general manager Ronald Seeliger emphasized that "the acquisition of the BIOTA intima brand represents a significant step in the company's strategy and creates new opportunities."

"Our mission is to provide the best possible support for the health of all women. With the BIOTA intima brand, in addition to enriching our portfolio, we also respond to the specific needs of women at different stages of life," Ronald said.

With the new acquisition, Hemofarm will provide even more efficient support in preserving women's health.

“By introducing the BIOTA intima brand to our offer, we are further strengthening our commitment to women's health. These products offer comprehensive support from microbiota balance to specific care for urinary and vaginal health,” said Ivana Bojbaša, Marketing Director for CHC/OTC at Hemofarm.

The BIOTA Intima brand includes products such as capsules (15 and 30 capsules), gel (100 ml) and cream (50 ml), carefully designed to meet the specific needs of women of all ages, who are increasingly paying attention to their intimate health.

By introducing the BIOTA intima brand, Hemofarm also continues to expand its gynecological portfolio, which includes brands such as Femmabiotic, Ferona, Miocystinn and Finderm Forte.